Tirzepatide is a novel dual agonist of the GIP and GLP-1 receptors, approved for glycemic control in adults with type 2 diabetes as well as for long-term weight management in individuals with a body mass index (BMI) ≥30 kg/m², or ≥27 kg/m² with at least one weight-related comorbidity.
For diabetes, it lowers both fasting and postprandial glucose by delaying gastric emptying, enhancing glucose-dependent insulin secretion, and suppressing glucagon release, with a lower risk of hypoglycemia compared to traditional insulin secretagogues. In obesity management, its dual central and peripheral actions reduce appetite and increase energy expenditure. Clinical trials have shown that 52–72 weeks of treatment can achieve an average body weight reduction of 15%–20%, accompanied by improvements in waist circumference, blood pressure, and triglycerides.
The most common adverse events are mild to moderate gastrointestinal symptoms, typically occurring in the first few weeks and mitigated by gradual dose escalation. Clinical initiation is recommended under the evaluation of an endocrinologist or weight-management specialist, with ongoing monitoring of glucose, body weight, and renal function. Overall, tirzepatide offers an evidence-based, safe, and sustainable therapeutic option for patients requiring both glycemic and weight control.
Post time: Aug-27-2025